Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment.
Saved in:
| Title: | Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. |
|---|---|
| Authors: | Vincent J (AUTHOR), Bernard GR (AUTHOR), Beale R (AUTHOR), Doig C (AUTHOR), Putensen C (AUTHOR), Dhainaut J (AUTHOR), Artigas A (AUTHOR), Fumagalli R (AUTHOR), Macias W (AUTHOR), Wright T (AUTHOR), Wong K (AUTHOR), Sundin DP (AUTHOR), Turlo MA (AUTHOR), Janes J (AUTHOR), ENHANCE Study Group (CORPORATE AUTHOR), Vincent, Jean-Louis1 (AUTHOR), Bernard, Gordon R (AUTHOR), Beale, Richard (AUTHOR), Doig, Christopher (AUTHOR), Putensen, Christian (AUTHOR) |
| Source: | Critical Care Medicine. Oct2005, Vol. 33 Issue 10, p2266-2277. 12p. |
| Database: | Academic Search Ultimate |
| ISSN: | 00903493 |
|---|---|
| DOI: | 10.1097/01.ccm.0000181729.46010.83 |
